Dactinomycin – Uses, Dosage, Side Effects, Interaction Dactinomycin is an intravenously administered, antineoplastic antibiotic that is used in the treatment of solid tumors in children and choriocarcinoma in adult women. In high doses, dactinomycin can cause severe liver injury including sinusoidal obstruction syndrome. Dactinomycin is a chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus. Dactinomycin intercalates between adjacent guanine–cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04) Mechanism of Action Good evidence exists that this drug bind strongly, but reversibly, to DNA, interfering with the synthesis of RNA (prevention of RNA polymerase elongation) and, consequently, with protein synthesis. The capacity of actinomycins to bind with double-helical DNA is responsible for their biological activity and cytotoxicity. X-ray studies of a crystalline complex between dactinomycin and deoxyguanosine permitted the formulation of a model that appears to explain the binding of the drug to DNA. The planar phenazone ring intercalates between adjacent guanine–cytosine base pairs of DNA, while the polypeptide chains extend along the minor groove of the helix. The summation of these interactions provides great stability to the dactinomycin-DNA complex, and as a result of the binding of dactinomycin, the transcription of DNA by RNA polymerase is blocked. DNA-dependent RNA polymerases are much more sensitive to the effects of dactinomycin than DNA polymerases. In addition, dactinomycin causes single-strand breaks in DNA, possibly through a free-radical intermediate or as a result of the action of topoisomerase II or Dactinomycin is an antineoplastic antibiotic. The drug has bacteriostatic activity, particularly against gram-positive organisms, but its cytotoxicity precludes its use as an anti-infective agent. Although the exact mechanism(s) of action has not been fully elucidated, the drug appears to inhibit DNA-dependent RNA synthesis by forming a complex with DNA by intercalating with guanine residues and impairing the template activity of DNA. Protein and DNA synthesis are also inhibited but less extensively and at higher concentrations of dactinomycin than are needed to inhibit RNA synthesis. Dactinomycin is immunosuppressive and also possesses some hypocalcemic activity similar to plicamycin. In cell biology, actinomycin D is shown to have the ability to inhibit transcription. Actinomycin D does this by binding DNA at the transcription initiation complex and preventing elongation of the RNA chain by RNA polymerase. Indications Antineoplastic; Anti-Bacterial Agents; Nucleic Acid Synthesis Inhibitors; Protein Synthesis Inhibitors For the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma, and metastatic, nonseminomatous testicular cancer as part of a combination chemotherapy and/or multi-modality treatment regimen Dactinomycin is an intravenously administered, antineoplastic antibiotic that is used in the treatment of solid tumors in children and choriocarcinoma in adult women. In high doses, dactinomycin can cause severe liver injury including sinusoidal obstruction syndrome. Dactinomycin, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. Dactinomycin is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. Dactinomycin, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Ewing’s Sarcoma Gestational Trophoblastic Disease Ovarian Cancer Rhabdomyosarcomas Sarcoma, Osteogenic Wilms’ tumor Metastatic nonseminomatous Testicular cancer Use in Cancer Dactinomycin is approved to be used alone or with other drugs to treat: Ewing sarcoma in adults and children. Gestational trophoblastic disease in adults and children. Rhabdomyosarcoma in adults and children. Solid tumors that are locally recurrent. It is used as palliative and/or adjuvant therapy in adults. Testicular cancer. It is used in adults and children whose nonseminomas have metastasized (spread to other parts of the body). Wilms tumor in adults and children. Dactinomycin is also being studied in the treatment of other types of cancer. Contraindications shingles a bad infection low blood counts due to bone marrow failure anemia decreased blood platelets low levels of white blood cells low levels of a type of white blood cell called neutrophils a blood clot in a vein of the liver liver problems ascites abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding infection caused by the varicella zoster virus exposure to the chickenpox Dosage Strengths: 0.5 mg Wilms’ Tumor As part of a multi-agent combination chemotherapy regimen: 45 mcg/kg IV over 10 to 15 minutes once every 3 to 6 weeks for up to 26 weeks For the treatment of Wilms tumor as part of a multi-phase combination chemotherapy regimen Rhabdomyosarcoma As part of a multi-agent combination chemotherapy regimen: 15 mcg/kg IV over 10 to 15 minutes once daily for 5 days every 3 to 9 weeks for up to 112 weeks For the treatment of rhabdomyosarcoma as part of a multi-phase combination chemotherapy regimen Ewing’s Sarcoma As part of a multi-agent combination chemotherapy regimen: 1250 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 51 weeks For the treatment of Ewing sarcoma as part of a multi-phase combination chemotherapy regimen Testicular Cancer As part of a cisplatin-based multi-agent combination chemotherapy regimen: 1000 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 12 weeks For the treatment of metastatic non-seminomatous testicular cancer as part of a multi-phase combination chemotherapy regimen Trophoblastic Disease As a single agent for nonmetastatic and low-risk metastatic disease: 12 mcg/kg IV over 10 to 15 minutes daily for 5 days As part of a multi-agent combination chemotherapy regimen for high-risk metastatic disease: 500 mcg IV over 10 to 15 minutes Days 1 and 2 every 2 weeks for up to 8 weeks For the treatment of post-menarchal patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen Solid Tumors In combination with melphalan for the lower extremity or pelvis: 50 mcg/kg IV over 10 to 15 minutes once In combination with melphalan for the upper extremity: 35 mcg/kg IV once For the treatment of adult patients with locally recurrent or locoregional solid malignancies as a component of palliative or adjunctive regional perfusion Pediatric Dose Wilms’ Tumor As part of a multi-agent combination chemotherapy regimen: 45 mcg/kg IV over 10 to 15 minutes once every 3 to 6 weeks for up to 26 weeks For the treatment of Wilms tumor as part of a multi-phase combination chemotherapy regimen Rhabdomyosarcoma As part of a multi-agent combination chemotherapy regimen: 15 mcg/kg IV over 10 to 15 minutes once daily for 5 days every 3 to 9 weeks for up to 112 weeks For the treatment of rhabdomyosarcoma as part of a multi-phase combination chemotherapy regimen Ewing’s Sarcoma As part of a multi-agent combination chemotherapy regimen: 1250 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 51 weeks For the treatment of Ewing sarcoma as part of a multi-phase combination chemotherapy regimen Testicular Cancer As part of a cisplatin-based multi-agent combination chemotherapy regimen: 1000 mcg/m2 IV over 10 to 15 minutes once every 3 weeks for 12 weeks For the treatment of metastatic non-seminomatous testicular cancer as part of a multi-phase combination chemotherapy regimen Trophoblastic Disease As a single agent for nonmetastatic and low-risk metastatic disease: 12 mcg/kg IV over 10 to 15 minutes daily for 5 days As part of a multi-agent combination chemotherapy regimen for high-risk metastatic disease: 500 mcg IV over 10 to 15 minutes Days 1 and 2 every 2 weeks for up to 8 weeks For the treatment of post-menarchal pediatric patients with gestational trophoblastic neoplasia as a single agent or as part of a combination chemotherapy regimen Administration advice: Administer the diluted reconstituted product IV over 10 to 15 minutes. Do not use in-line filters with a cellulose ester membrane. Side Effects The Most Common Common adverse drug reaction includes bone marrow suppression, fatigue, hair loss, mouth ulcer, loss of appetite and diarrhea. Actinomycin is a vesicant if extravasation occurs. vomiting stomach pain diarrhea hair loss hives rash difficulty breathing or swallowing nausea extreme tiredness unusual bleeding or bruising sores in the mouth and throat lack of energy loss of appetite pain in the upper right part of the stomach yellowing of the skin or eyes fever, sore throat, ongoing cough and congestion, or other signs of infection unusual bleeding or bruising black and tarry stools red blood in stools More Common sores in the mouth and throat fever, sore throat, chills, or other signs of infection black and tarry stools red blood in stools nausea extreme tiredness unusual bleeding or bruising lack of energy loss of appetite pain in the upper right part of the stomach yellowing of the skin or eyes flu-like symptoms decreased urination swelling of the face, arms, hands, feet, ankles, or lower legs blisters or rash swelling or tenderness in your stomach (upper right side), rapid weight gain; swelling in your arms or legs; dark urine, jaundice (yellowing of the skin or eyes); redness of your skin or the inside of your mouth and throat (if you are also receiving radiation treatment); sores or white patches in or around your mouth, trouble swallowing or talking, dry mouth, bad breath, altered sense of taste; blisters, ulcers, or other skin changes where an injection was given; or low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands, and feet, feeling light-headed or short of breath. Rare constipation fatigue nausea and vomiting skin darkening or redness of areas where radiation was given skin rash or acne temporary loss of hair diarrhea difficulty swallowing pain, redness, or swelling at the place of injection signs of infection such as fever higher than 38°C (100°F), chills, sweating, sore throat, coughing, painful urination, unusual vaginal itching or discharge, or redness or swelling around a cut, wound, or catheter site sores in mouth stomach pain symptoms of anemia such as fatigue, weakness, or shortness of breath symptoms of liver problems such as yellow eyes or skin, swelling or enlargement of the abdomen, dark urine, pale stools, nausea, or vomiting unusual bleeding (e.g., black or tarry stools or blood in the urine) or bruising weight loss symptoms of a severe allergic reaction such as hives, difficulty breathing, or swelling of the mouth or throat symptoms of a severe skin reaction (e.g., blistering, peeling, a rash covering a large area of the body, a rash that spreads quickly, or a rash combined with fever or discomfort) Drug interactions DRUG INTERACTION Abatacept The risk or severity of adverse effects can be increased when Dactinomycin is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Dactinomycin. Abemaciclib Abemaciclib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Abrocitinib The serum concentration of Dactinomycin can be increased when it is combined with Abrocitinib. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dactinomycin. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dactinomycin. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Dactinomycin. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Dactinomycin. Afatinib The serum concentration of Dactinomycin can be increased when it is combined with Afatinib. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dactinomycin. Alectinib Alectinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Dactinomycin. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dactinomycin. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Dactinomycin. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Dactinomycin. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Dactinomycin. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Dactinomycin. Ambrisentan The serum concentration of Dactinomycin can be increased when it is combined with Ambrisentan. Amiodarone The serum concentration of Dactinomycin can be increased when it is combined with Amiodarone. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Dactinomycin. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Dactinomycin. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Dactinomycin. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Dactinomycin. Anifrolumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Dactinomycin. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dactinomycin. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Dactinomycin. Antilymphocyte The risk or severity of adverse effects can be increased when Dactinomycin is combined with Antilymphocyte immunoglobulin (horse). Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dactinomycin. Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Dactinomycin. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dactinomycin. Apalutamide The serum concentration of Dactinomycin can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Dactinomycin can be increased when it is combined with Apixaban. Apremilast The risk or severity of adverse effects can be increased when Dactinomycin is combined with Apremilast. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Dactinomycin. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Dactinomycin. Arsenic trioxide The serum concentration of Dactinomycin can be increased when it is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Articaine. Asciminib The serum concentration of Dactinomycin can be increased when it is combined with Asciminib. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Dactinomycin. Asunaprevir The serum concentration of Dactinomycin can be increased when it is combined with Asunaprevir. Avanafil Avanafil may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Avatrombopag Avatrombopag may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Axitinib The serum concentration of Axitinib can be increased when it is combined with Dactinomycin. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Dactinomycin. Azathioprine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Azathioprine. live antigen The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Dactinomycin. calmette-guerin The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Dactinomycin. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Dactinomycin. Baricitinib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Dactinomycin. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Dactinomycin. Beclomethasone The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Dactinomycin. Belantamab The serum concentration of Dactinomycin can be increased when it is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Dactinomycin is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Dactinomycin is combined with Belinostat. Belumosudil The serum concentration of Dactinomycin can be increased when it is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Dactinomycin. Bendamustine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Dactinomycin. Benzocaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Dactinomycin. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Benzyl alcohol. Berotralstat The serum concentration of Dactinomycin can be increased when it is combined with Berotralstat. Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Dactinomycin. Betrixaban The serum concentration of Dactinomycin can be increased when it is combined with Betrixaban. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Dactinomycin. Bimekizumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bimekizumab. Binimetinib The serum concentration of Binimetinib can be increased when it is combined with Dactinomycin. Bisoprolol The serum concentration of Dactinomycin can be increased when it is combined with Bisoprolol. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Dactinomycin. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Dactinomycin. Blinatumomab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Blinatumomab. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Dactinomycin. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Dactinomycin. Bosutinib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bosutinib. Brentuximab vedotin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Brentuximab vedotin. Brigatinib Brigatinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Brodalumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Brodalumab. Budesonide The risk or severity of adverse effects can be increased when Dactinomycin is combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Bupivacaine. Buprenorphine Buprenorphine may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Busulfan The risk or severity of adverse effects can be increased when Dactinomycin is combined with Busulfan. Butacaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Butamben. Cabazitaxel The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cabazitaxel. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Dactinomycin. Caffeine Caffeine may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Canagliflozin The serum concentration of Dactinomycin can be increased when it is combined with Canagliflozin. Canakinumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Dactinomycin. Cannabidiol Cannabidiol may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Capecitabine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Dactinomycin. Capmatinib The serum concentration of Dactinomycin can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Capsaicin. Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dactinomycin. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Dactinomycin. Carfilzomib The serum concentration of Dactinomycin can be increased when it is combined with Carfilzomib. You Might Also Read Dapsona - Uses, Dosage, Side Effects, Interactions Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Dactinomycin. Carvedilol The serum concentration of Dactinomycin can be increased when it is combined with Carvedilol. Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Dactinomycin. Certolizumab pegol The risk or severity of adverse effects can be increased when Dactinomycin is combined with Certolizumab pegol. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dactinomycin. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Dactinomycin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Chloroprocaine. Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Dactinomycin. Cholesterol Cholesterol may increase the excretion rate of Dactinomycin which could result in a lower serum level and potentially a reduction in efficacy. Ciclesonide The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ciclesonide. Cilostazol The risk or severity of bleeding can be increased when Cilostazol is combined with Dactinomycin. Cinchocaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Cinchocaine. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Dactinomycin. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Dactinomycin. Clarithromycin The serum concentration of Dactinomycin can be increased when it is combined with Clarithromycin. Clobazam The serum concentration of Dactinomycin can be increased when it is combined with Clobazam. Clobetasol propionate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Dactinomycin. Clofazimine The serum concentration of Dactinomycin can be increased when it is combined with Clofazimine. Clomifene The serum concentration of Dactinomycin can be increased when it is combined with Clomifene. Clopidogrel The risk or severity of bleeding can be increased when Clopidogrel is combined with Dactinomycin. Clostridium tetani The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dactinomycin. Clozapine The risk or severity of neutropenia can be increased when Dactinomycin is combined with Clozapine. Cobicistat The serum concentration of Dactinomycin can be increased when it is combined with Cobicistat. Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Dactinomycin. Cocaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Cocaine. Colchicine The serum concentration of Dactinomycin can be increased when it is combined with Colchicine. Conivaptan The serum concentration of Dactinomycin can be increased when it is combined with Conivaptan. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Dactinomycin. Corticotropin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Corticotropin. Cortisone acetate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Dactinomycin. Crizotinib The serum concentration of Dactinomycin can be increased when it is combined with Crizotinib. Curcumin The serum concentration of Dactinomycin can be increased when it is combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dactinomycin. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Dactinomycin. Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dactinomycin. Cyclosporine Dactinomycin may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Dactinomycin. Cytarabine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Dactinomycin. Dabigatran etexilate The serum concentration of Dactinomycin can be increased when it is combined with Dabigatran etexilate. Dabrafenib Dabrafenib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dactinomycin. Daclatasvir The serum concentration of Dactinomycin can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Dactinomycin can be increased when it is combined with Dacomitinib. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Dactinomycin. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Dactinomycin. Daptomycin The serum concentration of Dactinomycin can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dactinomycin. Darolutamide Darolutamide may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Darunavir The serum concentration of Dactinomycin can be increased when it is combined with Darunavir. Dasabuvir Dasabuvir may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Dasatinib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Dasatinib. Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dactinomycin. Decitabine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Decitabine. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Dactinomycin. Deflazacort The risk or severity of adverse effects can be increased when Dactinomycin is combined with Deflazacort. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Dactinomycin. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Dactinomycin. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Dactinomycin. Deucravacitinib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Deucravacitinib. Dexamethasone The risk or severity of adverse effects can be increased when Dactinomycin is combined with Dexamethasone. Dexamethasone acetate The serum concentration of Dactinomycin can be decreased when it is combined with Dexamethasone acetate. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dactinomycin. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Dactinomycin. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Dactinomycin. Diethylstilbestrol Diethylstilbestrol may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Difluocortolone The risk or severity of adverse effects can be increased when Dactinomycin is combined with Difluocortolone. Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Dactinomycin. Digoxin The serum concentration of Dactinomycin can be increased when it is combined with Digoxin. Dimethyl fumarate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Dimethyl fumarate. Dinutuximab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Dinutuximab. Diosmin The serum concentration of Dactinomycin can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Dactinomycin. Diroximel fumarate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Diroximel fumarate. Docetaxel The risk or severity of adverse effects can be increased when Dactinomycin is combined with Docetaxel. Dolutegravir The serum concentration of Dactinomycin can be increased when it is combined with Dolutegravir. Doxorubicin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Doxorubicin. Dronedarone The serum concentration of Dactinomycin can be increased when it is combined with Dronedarone. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Dactinomycin. Duvelisib The serum concentration of Dactinomycin can be increased when it is combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Dyclonine. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Dactinomycin. Eculizumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Dactinomycin. Edoxaban The serum concentration of Dactinomycin can be increased when it is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Dactinomycin. Elagolix The serum concentration of Dactinomycin can be increased when it is combined with Elagolix. Elbasvir Elbasvir may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Eliglustat The serum concentration of Dactinomycin can be increased when it is combined with Eliglustat. Eltrombopag Eltrombopag may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Emapalumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Emapalumab. Enasidenib The serum concentration of Dactinomycin can be increased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Dactinomycin can be increased when it is combined with Enfortumab vedotin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Dactinomycin. Entrectinib The serum concentration of Dactinomycin can be increased when it is combined with Entrectinib. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Dactinomycin. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Dactinomycin. Erdafitinib The serum concentration of Dactinomycin can be increased when it is combined with Erdafitinib. Eribulin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Eribulin. Erlotinib Erlotinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Ertugliflozin The serum concentration of Dactinomycin can be increased when it is combined with Ertugliflozin. Erythromycin The serum concentration of Dactinomycin can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dactinomycin. Estradiol Estradiol may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Estradiol acetate Estradiol acetate may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Estradiol benzoate Estradiol benzoate may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Estradiol cypionate Estradiol cypionate may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Estradiol dienanthate Estradiol dienanthate may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Estradiol valerate Estradiol valerate may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Estramustine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Estramustine. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Dactinomycin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Etidocaine. Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Dactinomycin. Everolimus The serum concentration of Dactinomycin can be increased when it is combined with Everolimus. Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Dactinomycin. Favipiravir The serum concentration of Dactinomycin can be increased when it is combined with Favipiravir. Febuxostat The excretion of Dactinomycin can be decreased when combined with Febuxostat. Fedratinib The serum concentration of Dactinomycin can be increased when it is combined with Fedratinib. Fexofenadine The serum concentration of Dactinomycin can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Dactinomycin can be increased when it is combined with Filgotinib. Fingolimod Dactinomycin may increase the immunosuppressive activities of Fingolimod. Flibanserin The serum concentration of Dactinomycin can be increased when it is combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Dactinomycin. Fluconazole The serum concentration of Dactinomycin can be increased when it is combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dactinomycin. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Dactinomycin. Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Dactinomycin. Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Dactinomycin. Fluocinonide The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluocinonide. Fluocortolone The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Dactinomycin. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dactinomycin. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dactinomycin. Fluprednisolone The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluprednisolone. Fluticasone The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluticasone. Fluticasone furoate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluticasone furoate. Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dactinomycin. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Dactinomycin. Fostamatinib Fostamatinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Fostemsavir Fostemsavir may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Fusidic acid Fusidic acid may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Futibatinib The serum concentration of Dactinomycin can be increased when it is combined with Futibatinib. Gallium nitrate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Gallium nitrate. Gefitinib Gefitinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Dactinomycin. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dactinomycin. Gilteritinib Gilteritinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Glasdegib The serum concentration of Dactinomycin can be increased when it is combined with Glasdegib. Glatiramer The risk or severity of adverse effects can be increased when Dactinomycin is combined with Glatiramer. Glecaprevir The serum concentration of Dactinomycin can be increased when it is combined with Glecaprevir. Golimumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Golimumab. Grazoprevir Grazoprevir may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Guselkumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Guselkumab. Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Dactinomycin. Heparin The risk or severity of bleeding can be increased when Heparin is combined with Dactinomycin. Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dactinomycin. Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dactinomycin. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Dactinomycin. Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Dactinomycin. Hydrocortisone acetate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hydrocortisone acetate. Hydrocortisone butyrate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hydrocortisone butyrate. Hydrocortisone succinate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hydrocortisone succinate. Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Dactinomycin. Hydroxychloroquine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hydroxychloroquine. Hydroxyurea The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hydroxyurea. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dactinomycin. Ibrutinib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ibrutinib. Icosapent The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dactinomycin. Idarubicin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Idarubicin. Idelalisib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Idelalisib. Ifosfamide The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ifosfamide. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Dactinomycin. Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Dactinomycin. Imipramine The serum concentration of Imipramine can be increased when it is combined with Dactinomycin. Indacaterol The serum concentration of Dactinomycin can be increased when it is combined with Indacaterol. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Dactinomycin. Inebilizumab The risk or severity of infection can be increased when Dactinomycin is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Dactinomycin. You Might Also Read Brentuximab Vedotin - Uses, Dosage, Side Effects, Interactions Ketoconazole The serum concentration of Dactinomycin can be increased when it is combined with Ketoconazole. Lansoprazole Lansoprazole may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Lapatinib The serum concentration of Dactinomycin can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Dactinomycin can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Dactinomycin can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Dactinomycin can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Dactinomycin can be increased when it is combined with Lefamulin. Leflunomide The risk or severity of adverse effects can be increased when Dactinomycin is combined with Leflunomide. Lemborexant The serum concentration of Dactinomycin can be increased when it is combined with Lemborexant. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Dactinomycin. Lenvatinib The serum concentration of Dactinomycin can be increased when it is combined with Lenvatinib. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Dactinomycin. Letermovir Letermovir may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Levobupivacaine. Levoketoconazole The serum concentration of Dactinomycin can be increased when it is combined with Levoketoconazole. Levothyroxine The serum concentration of Dactinomycin can be decreased when it is combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Lidocaine. Linagliptin The serum concentration of Dactinomycin can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Dactinomycin. Lipegfilgrastim Dactinomycin may increase the myelosuppressive activities of Lipegfilgrastim. Lomitapide The serum concentration of Dactinomycin can be increased when it is combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Lomustine. Lonafarnib The serum concentration of Dactinomycin can be increased when it is combined with Lonafarnib. Loncastuximab tesirine The serum concentration of Dactinomycin can be increased when it is combined with Loncastuximab tesirine. Loperamide The serum concentration of Dactinomycin can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Dactinomycin can be increased when it is combined with Lopinavir. Lorlatinib The serum concentration of Dactinomycin can be decreased when it is combined with Lorlatinib. Loxapine The serum concentration of Dactinomycin can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Dactinomycin can be decreased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Dactinomycin can be increased when it is combined with Lusutrombopag. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Dactinomycin. Mannitol The serum concentration of Dactinomycin can be increased when it is combined with Mannitol. Maribavir The serum concentration of Dactinomycin can be increased when it is combined with Maribavir. Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Dactinomycin. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Dactinomycin. Mefloquine The serum concentration of Dactinomycin can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Dactinomycin is combined with Melphalan. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Dactinomycin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mepolizumab. Meprednisone The risk or severity of adverse effects can be increased when Dactinomycin is combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mercaptopurine. Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Dactinomycin. Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Dactinomycin. Methoxy polyethylen The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dactinomycin. Methylene blue The serum concentration of Dactinomycin can be increased when it is combined with Methylene blue. Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dactinomycin. Mifepristone The serum concentration of Dactinomycin can be decreased when it is combined with Mifepristone. Mirabegron The serum concentration of Dactinomycin can be increased when it is combined with Mirabegron. Mitapivat The serum concentration of Dactinomycin can be increased when it is combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Dactinomycin. Mitoxantrone The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mitoxantrone. COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Dactinomycin. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Dactinomycin. Mometasone furoate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Monomethyl fumarate. Morphine The serum concentration of Dactinomycin can be increased when it is combined with Morphine. Mosunetuzumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mosunetuzumab. Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Dactinomycin. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Dactinomycin. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dactinomycin. Mycophenolic acid The risk or severity of adverse effects can be increased when Dactinomycin is combined with Mycophenolic acid. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Dactinomycin. Natalizumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Natalizumab. Nelarabine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Nelarabine. Nelfinavir Nelfinavir may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Neratinib The serum concentration of Dactinomycin can be increased when it is combined with Neratinib. Netupitant The serum concentration of Dactinomycin can be increased when it is combined with Netupitant. Nilotinib The serum concentration of Dactinomycin can be increased when it is combined with Nilotinib. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Dactinomycin. Nintedanib The serum concentration of Dactinomycin can be increased when it is combined with Nintedanib. Norgestimate The serum concentration of Dactinomycin can be increased when it is combined with Norgestimate. Nortriptyline The serum concentration of Nortriptyline can be increased when it is combined with Dactinomycin. Novobiocin Novobiocin may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Dactinomycin. Obinutuzumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Dactinomycin. Ofatumumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ofatumumab. Olaparib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Olaparib. Omadacycline The serum concentration of Dactinomycin can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Dactinomycin can be increased when it is combined with Ombitasvir. Omeprazole Omeprazole may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Osimertinib Osimertinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Oteseconazole The serum concentration of Dactinomycin can be increased when it is combined with Oteseconazole. Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dactinomycin. Oxetacaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Oxetacaine. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Oxybuprocaine. Ozanimod The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Dactinomycin is combined with Paclitaxel. Pacritinib The serum concentration of Dactinomycin can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Dactinomycin can be increased when it is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Dactinomycin. Paliperidone The serum concentration of Dactinomycin can be increased when it is combined with Paliperidone. Panobinostat The risk or severity of adverse effects can be increased when Dactinomycin is combined with Panobinostat. Pantoprazole Pantoprazole may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Paritaprevir Paritaprevir may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Dactinomycin. Pazopanib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pazopanib. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dactinomycin. Pegcetacoplan The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Dactinomycin. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dactinomycin. Peginterferon The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Dactinomycin. Peginterferon The risk or severity of adverse effects can be increased when Dactinomycin is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Dactinomycin. Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Dactinomycin. Pentosan The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Dactinomycin. Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Dactinomycin. Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Dactinomycin. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Dactinomycin. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Dactinomycin. Phenol The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Phenol. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Dactinomycin. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dactinomycin. Pibrentasvir The serum concentration of Dactinomycin can be increased when it is combined with Pibrentasvir. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dactinomycin. Pirfenidone The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pirfenidone. Pitolisant The serum concentration of Dactinomycin can be increased when it is combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Dactinomycin. Pomalidomide The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pomalidomide. Ponatinib The serum concentration of Dactinomycin can be increased when it is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ponesimod. Posaconazole The serum concentration of Dactinomycin can be increased when it is combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pralatrexate. Pralsetinib The serum concentration of Dactinomycin can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Dactinomycin. Pravastatin Pravastatin may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Dactinomycin. Prednisolone phosphate The serum concentration of Dactinomycin can be decreased when it is combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Dactinomycin. Prilocaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Prilocaine. Procaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Dactinomycin is combined with Procarbazine. Progesterone Progesterone may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Propafenone The serum concentration of Dactinomycin can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Proparacaine. Propoxycaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Propoxycaine. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dactinomycin. Protein C The risk or severity of bleeding can be increased when Protein C is combined with Dactinomycin. Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Dactinomycin. Quinidine The serum concentration of Dactinomycin can be increased when it is combined with Quinidine. Quinine The serum concentration of Dactinomycin can be increased when it is combined with Quinine. Rabeprazole Rabeprazole may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Dactinomycin. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dactinomycin. Rabies virus The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Dactinomycin. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dactinomycin. Ranolazine The serum concentration of Dactinomycin can be increased when it is combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ravulizumab. Regorafenib The serum concentration of Dactinomycin can be increased when it is combined with Regorafenib. Relugolix The serum concentration of Dactinomycin can be increased when it is combined with Relugolix. Reserpine The serum concentration of Dactinomycin can be increased when it is combined with Reserpine. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Dactinomycin. Revefenacin The serum concentration of Dactinomycin can be increased when it is combined with Revefenacin. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Dactinomycin. Rifampicin The serum concentration of Dactinomycin can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Dactinomycin can be increased when it is combined with Rifamycin. Rilonacept The risk or severity of adverse effects can be increased when Dactinomycin is combined with Rilonacept. Rilpivirine Rilpivirine may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Rimegepant The serum concentration of Dactinomycin can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Dactinomycin can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Dactinomycin can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Risankizumab. Ritonavir The serum concentration of Dactinomycin can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Dactinomycin. Rivaroxaban The serum concentration of Dactinomycin can be increased when it is combined with Rivaroxaban. Roflumilast Roflumilast may increase the immunosuppressive activities of Dactinomycin. Rolapitant The serum concentration of Dactinomycin can be increased when it is combined with Rolapitant. Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Dactinomycin. Ropeginterferon The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Ropivacaine. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Dactinomycin. Roxadustat The serum concentration of Dactinomycin can be increased when it is combined with Roxadustat. Rubella virus The risk or severity of infection can be increased when Rubella virus vaccine is combined with Dactinomycin. Rucaparib Rucaparib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Ruxolitinib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ruxolitinib. Safinamide Safinamide may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Sapropterin The serum concentration of Dactinomycin can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Dactinomycin can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Dactinomycin can be increased when it is combined with Sarecycline. Sarilumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Satralizumab You Might Also Read Duvelisib - Uses, Dosage, Side Effects, Interaction Secukinumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Secukinumab. Selexipag The serum concentration of Dactinomycin can be increased when it is combined with Selexipag. Selumetinib The serum concentration of Dactinomycin can be increased when it is combined with Selumetinib. Sildenafil The serum concentration of Dactinomycin can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Dactinomycin can be increased when it is combined with Silodosin. Siltuximab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Siltuximab. Simeprevir The serum concentration of Dactinomycin can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Dactinomycin can be increased when it is combined with Simvastatin. Siponimod The risk or severity of adverse effects can be increased when Dactinomycin is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dactinomycin. Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Dactinomycin. Sitagliptin The serum concentration of Dactinomycin can be increased when it is combined with Sitagliptin. Smallpox The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Dactinomycin. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Dactinomycin. Sofosbuvir The serum concentration of Dactinomycin can be increased when it is combined with Sofosbuvir. Sorafenib The serum concentration of Dactinomycin can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Dactinomycin can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Dactinomycin can be increased when it is combined with Sotorasib. Spesolimab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Spesolimab. St. John’s Wort The serum concentration of Dactinomycin can be decreased when it is combined with St. John’s Wort. Stiripentol The excretion of Dactinomycin can be decreased when combined with Stiripentol. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Dactinomycin. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Dactinomycin. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Dactinomycin. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dactinomycin. Sulfinpyrazone The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Dactinomycin. Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Dactinomycin. Sunitinib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Sunitinib. Suvorexant The serum concentration of Dactinomycin can be increased when it is combined with Suvorexant. Tacrolimus Tacrolimus may increase the immunosuppressive activities of Dactinomycin. Tafamidis The serum concentration of Dactinomycin can be increased when it is combined with Tafamidis. Talazoparib The serum concentration of Talazoparib can be increased when it is combined with Dactinomycin. Tamoxifen The serum concentration of Dactinomycin can be increased when it is combined with Tamoxifen. Taurocholic acid Taurocholic acid may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Tazemetostat The serum concentration of Dactinomycin can be increased when it is combined with Tazemetostat. Technetium The serum concentration of Dactinomycin can be increased when it is combined with Technetium Tc-99m sestamibi. Tedizolid The risk or severity of myelosuppression can be increased when Dactinomycin is combined with Tedizolid phosphate. Tegaserod The serum concentration of Dactinomycin can be increased when it is combined with Tegaserod. Telaprevir The serum concentration of Dactinomycin can be increased when it is combined with Telaprevir. Telmisartan Telmisartan may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Dactinomycin. Temsirolimus The serum concentration of Dactinomycin can be increased when it is combined with Temsirolimus. Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Dactinomycin. Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Dactinomycin. Tenofovir disoproxil The serum concentration of Dactinomycin can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Dactinomycin can be increased when it is combined with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Teprotumumab. Teriflunomide The risk or severity of adverse effects can be increased when Dactinomycin is combined with Teriflunomide. Tetracaine The risk or severity of methemoglobinemia can be increased when Dactinomycin is combined with Tetracaine. Tezacaftor The serum concentration of Dactinomycin can be increased when it is combined with Tezacaftor. Thalidomide The risk or severity of adverse effects can be increased when Dactinomycin is combined with Thalidomide. Thiotepa The risk or severity of adverse effects can be increased when Dactinomycin is combined with Thiotepa. Ticagrelor The serum concentration of Dactinomycin can be increased when it is combined with Ticagrelor. encephalitis vaccine The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Dactinomycin. Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Dactinomycin. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Dactinomycin. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Dactinomycin. Tipranavir The serum concentration of Dactinomycin can be decreased when it is combined with Tipranavir. Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Dactinomycin. Tivozanib Tivozanib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Tixocortol The risk or severity of adverse effects can be increased when Dactinomycin is combined with Tixocortol. Tocilizumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Tocilizumab. Tofacitinib Dactinomycin may increase the immunosuppressive activities of Tofacitinib. Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Dactinomycin. Topotecan The risk or severity of adverse effects can be increased when Dactinomycin is combined with Topotecan. Toremifene The serum concentration of Dactinomycin can be increased when it is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Dactinomycin. Trabectedin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Trabectedin. Trastuzumab Trastuzumab may increase the neutropenic activities of Dactinomycin. Trastuzumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Trastuzumab emtansine. Trazodone The serum concentration of Dactinomycin can be decreased when it is combined with Trazodone. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Dactinomycin. Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Dactinomycin. Trichlormethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Dactinomycin. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Dactinomycin. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Dactinomycin. Trilaciclib The serum concentration of Dactinomycin can be increased when it is combined with Trilaciclib. Trilostane The risk or severity of adverse effects can be increased when Dactinomycin is combined with Trilostane. Trimipramine The serum concentration of Trimipramine can be increased when it is combined with Dactinomycin. Tucatinib Tucatinib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dactinomycin. Typhoid Vaccine The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Dactinomycin. polysaccharide The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Dactinomycin. Ubrogepant The serum concentration of Dactinomycin can be increased when it is combined with Ubrogepant. Umbralisib The serum concentration of Dactinomycin can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Dactinomycin can be increased when it is combined with Umeclidinium. Upadacitinib The risk or severity of adverse effects can be increased when Dactinomycin is combined with Upadacitinib. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Dactinomycin. Vandetanib The serum concentration of Dactinomycin can be increased when it is combined with Vandetanib. Vardenafil The serum concentration of Dactinomycin can be increased when it is combined with Vardenafil. Varicella The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Dactinomycin. Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Dactinomycin. Vedolizumab The risk or severity of adverse effects can be increased when Dactinomycin is combined with Vedolizumab. Velpatasvir The serum concentration of Dactinomycin can be increased when it is combined with Velpatasvir. Vemurafenib The serum concentration of Dactinomycin can be increased when it is combined with Vemurafenib. Venetoclax The serum concentration of Dactinomycin can be increased when it is combined with Venetoclax. Venlafaxine Venlafaxine may increase the excretion rate of Dactinomycin which could result in a lower serum level and potentially a reduction in efficacy. Verapamil The serum concentration of Dactinomycin can be increased when it is combined with Verapamil. Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Dactinomycin. Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Dactinomycin. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Dactinomycin. Vinflunine The serum concentration of Vinflunine can be increased when it is combined with Dactinomycin. Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Dactinomycin. Vismodegib Vismodegib may decrease the excretion rate of Dactinomycin which could result in a higher serum level. Voclosporin The serum concentration of Dactinomycin can be increased when it is combined with Voclosporin. Vorapaxar The serum concentration of Dactinomycin can be increased when it is combined with Vorapaxar. Vorinostat The risk or severity of adverse effects can be increased when Dactinomycin is combined with Vorinostat. Voxilaprevir The serum concentration of Dactinomycin can be increased when it is combined with Voxilaprevir. Warfarin The risk or severity of bleeding can be increased when Warfarin is combined with Dactinomycin. Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Dactinomycin. Yellow fever The risk or severity of infection can be increased when Yellow fever vaccine is combined with Dactinomycin. Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Dactinomycin. Zonisamide The serum concentration of Dactinomycin can be increased when it is combined with Zonisamide. Pregnancy and Lactation FDA Pregnancy Category B Pregnancy This medication should not be used during pregnancy unless the benefits outweigh the risks. Effective birth control should be practiced while using dactinomycin. If you become pregnant while using this medication, contact your doctor immediately. Lactation It is not known if dactinomycin passes into breast milk. Women should not breastfeed while receiving dactinomycin treatment due to the risk of potential harm to the infant. Talk to your doctor. This medication should be given to infants only over the age of 6 months. How should this medicine be used? Dactinomycin comes as a powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a medical facility. The length of treatment depends on the type of cancer you have, the types of other drugs you are taking, and how well your body responds to treatment. Your doctor may need to stop or delay your treatment if you experience certain side effects. Dactinomycin may also be injected by a doctor directly into a specific part of the body or the organ to treat the area where a tumor is located. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient Dactinomycin is also sometimes used to treat a type of cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed). Talk to your doctor about the risks of using this medication for your condition. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before receiving dactinomycin, tell your doctor and pharmacist if you are allergic to dactinomycin, any other medications, or any of the ingredients in dactinomycin injection. Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. tell your doctor if you have chickenpox or herpes zoster (shingles). Your doctor will probably not want you to receive a dactinomycin injection. tell your doctor if you have previously received or are currently receiving radiation therapy. tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant or breast-feed while you are receiving dactinomycin. If you become pregnant while receiving dactinomycin, call your doctor. Dactinomycin may harm the fetus. do not have any vaccinations without talking to your doctor. References https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050682s029s030lbl.pdf https://pubchem.ncbi.nlm.nih.gov/compound/Dactinomycin https://pubchem.ncbi.nlm.nih.gov/compound/2019 https://www.drugs.com/mtm/dactinomycin.html https://go.drugbank.com/drugs/DB00970 https://medlineplus.gov/druginfo/meds/a682224.html https://en.wikipedia.org/wiki/Dactinomycin https://www.webmd.com/drugs/2/drug-19921/dactinomycin-intravenous/details/list-contraindications ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1554/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=D003609 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/DACTINOMYCIN DrugBank https://www.drugbank.ca/legal/terms_of_use Dactinomycin https://www.drugbank.ca/drugs/DB00970 Therapeutic Target Database (TTD) Dactinomycin http://idrblab.net/ttd/data/drug/details/D0P8IV CAMEO Chemicals https://cameochemicals.noaa.gov/help/reference/terms_and_conditions.htm?d_f=false ACTINOMYCIN D https://cameochemicals.noaa.gov/chemical/19722 CAMEO Chemical Reactivity Classification https://cameochemicals.noaa.gov/browse/react ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Dactinomycin [USAN:USP:INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0000050760 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Actinomycin D https://comptox.epa.gov/dashboard/DTXSID9020031 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice Dactinomycin https://echa.europa.eu/substance-information/-/substanceinfo/100.000.058 Dactinomycin https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/88782 FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking DACTINOMYCIN https://gsrs.ncats.nih.gov/ginas/app/beta/substances/1CC1JFE158 Hazardous Substances Data Bank (HSDB) DACTINOMYCIN https://pubchem.ncbi.nlm.nih.gov/source/hsdb/3220 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Dactinomycin http://www.hmdb.ca/metabolites/HMDB0015105 HMDB0015105_msms_2253147 https://hmdb.ca/metabolites/HMDB0015105#spectra ChEBI Actinomycin D http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27666 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking DACTINOMYCIN https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Dactinomycin https://www.ncbi.nlm.nih.gov/books/n/livertox/Dactinomycin/ LOTUS – the natural products occurrence database LICENSE The code for LOTUS is released under the GNU General Public License v3.0. https://lotus.nprod.net/ LOTUS Tree https://lotus.naturalproducts.net/ NCI Thesaurus (NCIt) https://www.cancer.gov/policies/copyright-reuse https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C412 NCI Thesaurus Tree https://ncit.nci.nih.gov CCSbase DACTINOMYCIN CCSbase Classification https://ccsbase.net/ ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html DACTINOMYCIN https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=DACTINOMYCIN Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking dactinomycin https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset The Natural Products Atlas LICENSE The Natural Products Atlas is licensed under a Creative Commons Attribution 4.0 International License. https://www.npatlas.org/terms Actinomycin D https://www.npatlas.org/explore/compounds/NPA007563 The Natural Products Atlas Classification https://www.npatlas.org/ EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking DACTINOMYCIN https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory International Agency for Research on Cancer (IARC) https://publications.iarc.fr/Terms-Of-Use Actinomycin D https://monographs.iarc.who.int/list-of-classifications IARC Classification https://www.iarc.fr/ MassBank of North America (MoNA) LICENSE The content of the MoNA database is licensed under CC BY 4.0. https://mona.fiehnlab.ucdavis.edu/documentation/license Actinomycin D https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22RJURFGZVJUQBHK-IIXSONLDSA-N%22%27 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Cosmegen (Dactinomycin) https://www.cancer.gov/about-cancer/treatment/drugs/dactinomycin NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html dactinomycin https://rxnav.nlm.nih.gov/id/rxnorm/3100 PubChem https://pubchem.ncbi.nlm.nih.gov Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=90114615-889043108 WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Dactinomycin https://list.essentialmeds.org/medicines/83 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Dactinomycin https://www.wikidata.org/wiki/Q186127 Wiley https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=64721 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Dactinomycin https://www.ncbi.nlm.nih.gov/mesh/68003609 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Nucleic Acid Synthesis Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68019384 Protein Synthesis Inhibitors https://www.ncbi.nlm.nih.gov/mesh/68011500 Anti-Bacterial Agents https://www.ncbi.nlm.nih.gov/mesh/68000900 Antibiotics, Antineoplastic https://www.ncbi.nlm.nih.gov/mesh/68000903 UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ EPA Substance Registry Services LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources EPA SRS List Classification https://sor.epa.gov/sor_internet/registry/substreg/LandingPage.do PATENTSCOPE (WIPO) SID 388454111 https://pubchem.ncbi.nlm.nih.gov/substance/388454111 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More